سیویلیکا را در شبکه های اجتماعی دنبال نمایید.

Travel habits of patients with end-stage malignant diseases: a pilot study

Publish Year: 1403
Type: Journal paper
Language: English
View: 64

This Paper With 8 Page And PDF Format Ready To Download

Export:

Link to this Paper:

Document National Code:

JR_IJTMGH-12-1_007

Index date: 14 September 2024

Travel habits of patients with end-stage malignant diseases: a pilot study abstract

Demographic development and continuing improvements in supportive and antineoplastic therapies are reasonable predictors of increasing travel activities carried out by patients with malignant diseases. There is a lack of data on travel habits of patients with end-stage oncological diseases. We performed a multi-phased cross-sectional study to gain insights into the intersection of travel medicine and oncology. A total of 82 patients with 21 different cancer entities at a median age of 63 years completed the final questionnaire. 90.2% of all participants rated travelling as an important or very important aspect in their lives, of whom 73.2% had participated in a short- or holiday trip after the cancer diagnosis. All but one (98.8%) participant were about to plan a short- or holiday trip in the near future. Germany (home country) was the most important travel destination, ‘Relaxing’ and ‘enjoying nature’ were the most important travel motives. Fatigue and overall (medical) insecurities were major obstacles to carry out travel plans. In conclusion, a high proportion of patients enjoy travelling. Physicians and patients are encouraged to openly discuss holiday-taking in accordance with available guidelines. More research is needed to fully understand needs and obstacles at the crossroads of travel medicine and oncology.

Travel habits of patients with end-stage malignant diseases: a pilot study Keywords:

Travel habits of patients with end-stage malignant diseases: a pilot study authors

Jan Stratmann

Department of Medicine, Hematology/Oncology University Hospital Frankfurt, Goethe University, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Olivier Ballo

Goethe University Frankfurt

John Bitter

Department of Urology, University Clinic of Frankfurt, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Olav Heringer

Cancer Center, Wiesbaden, Germany

Fagr Eladly

Department of Medicine, Hematology/Oncology University Hospital Frankfurt, Goethe University, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Jonas Vischedyk

Department of Medicine, Hematology/Oncology University Hospital Frankfurt, Goethe University, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Sofia Hornetz

Department of Pediatrics, Sana Klinikum Offenbach GmbH, Offenbach, Germany

Sebastian Koschade

Department of Medicine, Hematology/Oncology University Hospital Frankfurt, Goethe University, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Nadija Hossini

Department of Medicine, Hematology/Oncology University Hospital Frankfurt, Goethe University, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Christian Brandts

Department of Medicine, Hematology/Oncology University Hospital Frankfurt, Goethe University, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Hubert Serve

Department of Medicine, Hematology/Oncology University Hospital Frankfurt, Goethe University, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Annika Wegener

University Cancer Center Frankfurt (UCT), University Clinic of Frankfurt, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Severine Banek

Department of Urology, University Clinic of Frankfurt, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Shabnam Shaid

Department of Medicine, Hematology/Oncology University Hospital Frankfurt, Goethe University, Theodor Stern Kai ۷, ۶۰۵۹۶ Frankfurt, Germany

Kerstin Wegener

Frankfurt University of Applied Sciences, Faculty of Business and Law, Nibelungenplatz ۱, ۶۰۳۱۸ Frankfurt, Germany